1)Sajatovic M, Jenkins JH:Is antipsychotic medication stigmatizing for people with mental illness? Int Rev Psychiatry 19:107-112, 2007[PMID:17464788]
2)Bebbington PE, Angermeyer M, Azorin JM, et al:Side-effects of antipsychotic medication and health-related quality of life in schizophrenia. Acta Psychiatr Scand Suppl 119:22-28, 2009[PMID:19132963]
3)Gibson TB, Jing Y, Kim E, et al:Cost-sharing effects on adherence and persistence for second-generation antipsychotics in commercially insured patients. Manag Care 19:40-47, 2010[PMID:20822071]
4)Asian Network of Early Psychosis Writing Group:Guidelines for discontinuation of antipsychotics in patients who recover from first-episode schizophrenia spectrum disorders:Derived from the aggregated opinions of Asian network of early psychosis experts and literature review. Int J Neuropsychopharmacol 25:737-758, 2022[PMID:35451023]
5)Keepers GA, Fochtmann LJ, Anzia JM, et al:The American Psychiatric Association practice guideline for the treatment of patients with schizophrenia. Am J Psychiatry 177:868-872, 2020[PMID:32867516]
6)Taipale H, Tanskanen A, Mehtälä J, et al:20-year follow-up study of physical morbidity and mortality in relationship to antipsychotic treatment in a nationwide cohort of 62,250 patients with schizophrenia(FIN20). World Psychiatry 19:61-68, 2020[PMID:31922669]
7)Vita A, Barlati S:Recovery from schizophrenia:Is it possible? Curr Opin Psychiatry 31:246-255, 2018[PMID:29474266]
8)McDonagh MS, Dana T, Kopelovich SL, et al:Psychosocial interventions for adults with schizophrenia:An overview and update of systematic reviews. Psychiatr Serv 73:299-312, 2022[PMID:34384230]
9)Solmi M, Croatto G, Piva G, et al:Efficacy and acceptability of psychosocial interventions in schizophrenia:Systematic overview and quality appraisal of the meta-analytic evidence. Mol Psychiatry 28:354-368, 2023[PMID:35999275]
10)Correll CU, Rubio JM, Kane JM:What is the risk-benefit ratio of long-term antipsychotic treatment in people with schizophrenia? World Psychiatry 17:149-160, 2018[PMID:29856543]
11)Rodolico A, Bighelli I, Avanzato C, et al:Family interventions for relapse prevention in schizophrenia:A systematic review and network meta-analysis. Lancet Psychiatry 9:211-221, 2022[PMID:35093198]
12)Guaiana G, Abbatecola M, Aali G, et al:Cognitive behavioural therapy(group)for schizophrenia. Cochrane Database Syst Rev 7:CD009608, 2022[PMID:35866377]
13)de Winter L, Couwenbergh C, van Weeghel J, et al:Who benefits from individual placement and support?:A meta-analysis. Epidemiol Psychiatric Sci 31:e50, 2022
14)Dieterich M, Irving CB, Bergman H, et al:Intensive case management for severe mental illness. Cochrane Database Syst Rev 1:CD007906, 2017[PMID:28067944]
15)Vita A, Barlati S, Ceraso A, et al:Effectiveness, core elements, and moderators of response of cognitive remediation for schizophrenia:A systematic review and meta-analysis of randomized clinical trials. JAMA Psychiatry 78:848-858, 2021[PMID:33877289]
16)Turner DT, McGlanaghy E, Cuijpers P, et al:A meta-analysis of social skills training and related interventions for psychosis. Schizophr Bull 44:475-491, 2018[PMID:29140460]
17)National Institute for Health and Care Excellence:Psychosis and schizophrenia in adults:Prevention and management. Clinical guidance[CG178], 2014 https://www.nice.org.uk/guidance/cg178/chapter/Recommendations[2024年9月30日閲覧]
18)Miller R, Pavlo AJ:Two experts, one goal:Collaborative deprescribing in psychiatry. Curr Psychiatry Rev 14:12-18, 2018